Reset
Showing 5 of 5 academic articles

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD • JTO Clinical and Research Reports (2021)

Introduction: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs). Novel EGFR TKIs have been developed or repurposed for these mutants. A ...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.jtocrr.2020.100105

Epidermal Growth Factor Induces Vasoconstriction Through the Phosphatidylinositol 3-Kinase-Mediated Mitogen-Activated Protein Kinase Pathway in Hypertensive Rats

Kim Junghwan, Lee Chang-Kwon, Park Hyo-Jun, Kim Hyo Jin et al. • Journal of Pharmacological Sciences (2006)

Abstract.: We investigated whether increased contractile responsiveness to epidermal growth factor (EGF) is associated with altered activation of mitogen-activated protein kinase (MAPK) in the aortic smooth muscle of deoxycorticosterone ace...

DOAJ Open Access (DOAJ) DOI: 10.1254/jphs.FP0060021

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling

Xindong Wei, Anfeng Si, Shuai Zhao, Yi Fu et al. • Cellular & Molecular Biology Letters (2025)

Abstract Background Circular (circ)RNAs have emerged as crucial contributors to cancer progression. Nonetheless, the expression regulation, biological functions, and underlying mechanisms of circRNAs in mediating hepatocellular carcinoma (H...

DOAJ Open Access (DOAJ) DOI: 10.1186/s11658-025-00690-1